June 27 (Reuters) - Janssen Inc
* Health Canada has approved invega trinza (paliperidone
palmitate), an antipsychotic medication for schizophrenia
* Health Canada's approval of invega trinza is based on two
randomized, double-blind trials
* Invega trinza provides a new dosing regimen option
administered only four times a year
Source text for Eikon: ID:nCNWfpgGSa
(Bengaluru Newsroom: +1 646 223 8780) June 27 (Reuters) - Janssen Inc JNJ.N
* Health Canada has approved Invega Trinza (paliperidone
palmitate), an antipsychotic medication for schizophrenia
* Health Canada's approval of Invega Trinza is based on
two randomized, double-blind trials
* Invega Trinza provides a new dosing regimen option
administered only four times a year
Source text for Eikon: ID:nCNWfpgGSa
Further company coverage: JNJ.N